Ponatinib (AP24534)

For research use only. Not for use in humans.

目录号：S1490

CAS No. 943319-70-8

Ponatinib (AP24534)是一种新型有效的多靶点抑制剂，在无细胞试验中作用于Abl，PDGFRα，VEGFR2，FGFR1和Src，IC50分别为0.37 nM，1.1 nM，1.5 nM，2.2 nM和5.4 nM。Ponatinib (AP24534)可抑制自噬。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 819.31	现货
10mg	RMB 903.01	现货
50mg	RMB 3034.48	现货
200mg	RMB 7959.08	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Ponatinib (AP24534)发表文献98篇：

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(4):431-443

PubMed: 31543464 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14329

PubMed: 25970250 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Cancer Cell, 2012, 22(5):656-67

PubMed: 23153538 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.32924

PubMed: 32064608 ( click the link to review the publication )

FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 10.1074/mcp.RA119.001504

PubMed: 32102969 ( click the link to review the publication )

J Infect Dis, 2020, 3;jiaa295

PubMed: 32492702 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Front Pharmacol, 2020, 30;11:543

PubMed: 32425788 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):592

PubMed: 32580713 ( click the link to review the publication )

Nature, 2020, 583(7818):845-851

PubMed: 32699415 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04022-x

PubMed: 31901955 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:408

PubMed: 32596239 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2020, 1;6(2) pii: a004838

PubMed: 31980503 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )
Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Protein Cell, 2019, 10(3):161-177

PubMed: 29667003 ( click the link to review the publication )

Br J Cancer, 2019, 120(6):612-620

PubMed: 30792533 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):1985-1996

PubMed: 31308077 ( click the link to review the publication )

FEBS J, 2019, 286(22):4443-4472

PubMed: 31155838 ( click the link to review the publication )

Front Oncol, 2019, 9:103

PubMed: 30931252 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Cell Cycle, 2019, 18(18):2307-2322

PubMed: 31349760 ( click the link to review the publication )

Transl Oncol, 2019, 12(9):1221-1228

PubMed: 31276961 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Exp Dermatol, 2019, 10.1111/exd.14010

PubMed: 31338879 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(2):126-136

PubMed: 30251267 ( click the link to review the publication )

Leukemia, 2019, 33(8):1964-1977

PubMed: 30842608 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(8):1932-1943

PubMed: 29440177 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Respir Res, 2018, 19(1):120

PubMed: 29921306 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Sci Adv, 2018, 4(11):eaau0731

PubMed: 30417093 ( click the link to review the publication )
Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):8

PubMed: 28069043 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-17-0008

PubMed: 28500237 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10-:2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:5519

PubMed: 28717217 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(6):1455-1467

PubMed: 27733071 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15219

PubMed: 29123157 ( click the link to review the publication )

Gut, 2016, 10.1136/gutjnl-2015-310382

PubMed: 26953272 ( click the link to review the publication )

Blood, 2016, 28;127(17):2131-43

PubMed: 26864341 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Cancer Sci, 2016, 107(2):140-8

PubMed: 26583567 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Tumour Biol, 2016, 37(2):2365-78

PubMed: 26373734 ( click the link to review the publication )

Genes Chromosomes Cancer, 2016, 55(1):60-8

PubMed: 26391436 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

Sci Transl Med, 2015, 7(298):298ra119

PubMed: 26223302 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Leukemia, 2015, 29(5)

PubMed: 25394714 ( click the link to review the publication )
Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

J Med Chem, 2015, 58(23):9228-37

PubMed: 26562217 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Toxicol Sci, 2015, 143(1):147-55

PubMed: 25304212 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120841

PubMed: 25803811 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(2):133-44

PubMed: 24463606 ( click the link to review the publication )

Sci Transl Med, 2014, 6(261):261ra152

PubMed: 25378644 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Genome Biol, 2014, 15(8):428

PubMed: 25315765 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1321173111

PubMed: 24550512 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

Structure, 2014, 22(12):1764-74

PubMed: 25465127 ( click the link to review the publication )

Oncol Rep, 2014, 31(4):1605-12

PubMed: 24481648 ( click the link to review the publication )

Thrombo Res, 2014, 135(1):155-60

PubMed: 25527332 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):54-60

PubMed: 24565842 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(9):1316-23

PubMed: 25122427 ( click the link to review the publication )

Harvard University, 2014, Rachel Grace Liao

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Cancer Res, 2013, 73(16):5195-205

PubMed: 23786770 ( click the link to review the publication )

Neoplasia, 2013, 15(8):975-88

PubMed: 23908597 ( click the link to review the publication )

Curr Cancer Drug Targets, 2012, 12(5):505-21

PubMed: 22483156 ( click the link to review the publication )
Exp Hematol, 2012, 41(4):335-45.e3

PubMed: 23287417 ( click the link to review the publication )

Mol Genet Metab, 2010, 100(4):309-15

PubMed: 20554235 ( click the link to review the publication )

产品安全说明书

Bcr-Abl抑制剂选择性比较

生物活性

产品描述

靶点

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	点击更多
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	点击更多

体外研究

Ponatinib是有效的可用于口服的多靶点激酶抑制剂，作用于野生型细胞,及T315I 突变细胞IC50分别为1.2和8.8nM。^[1] Ponatinib抑制Ba/F3衍生细胞系的增殖。^[2] Ponatinib作用于表达野生型或T315I突变型BCR-ABL的CML细胞系，有效抑制BCR-ABL调节的信号。Ponatinib阻断在细胞瘤筛选时产生抗性突变。^[3] Ponatinib也抑制VEGFR和FGFR家族激酶，在体外抑制FLT3, KIT, FGFR1,和PDGFRa激酶活性时IC50分别为13, 13, 2, 和1 nM.^[4]Ponatinib抑制全部4种RTKs磷酸化，存在剂量依赖性，IC50值为0.3到20 nM。然而，Ponatinib抑制表达野生型FLT3的RS4;11细胞时IC50>100 nM。

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	NUPtV4hMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPuUJJSUUN3ME2wMlAxODByMECzOVkh\|ryP	MYPTRW5ITVJ?
MV-4-11	MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXqdndKSzVyPUCuNFAxODl3NjFOwG0>	NYLoN5RoW0GQR1XS
MEG-01	M{[yOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnm0TWM2OD1yLkCwNFEzQCEQvF2=	NViwSmZKW0GQR1XS
LAMA-84	NIC5VnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLmSHJKSzVyPUCuNFAxOTZ3IN88US=>	NV7LPGVrW0GQR1XS
CGTH-W-1	M1nXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnKPIlKSzVyPUCuNFAyPjlizszN	Mom0V2FPT0WU
KASUMI-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rtTWlEPTB;MD6wNFIyPyEQvF2=	M1Hr[HNCVkeHUh?=
BE-13	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3CV2xKSzVyPUCuNFAzPTlizszN	NUXmVGR[W0GQR1XS
CTV-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrZU5ZKSzVyPUCuNFA2OjFizszN	MlKxV2FPT0WU
NKM-1	MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUm3SYluUUN3ME2wMlAxPjV3IN88US=>	NFrROlBUSU6JRWK=
MONO-MAC-6	NYHQVoQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHlTWM2OD1yLkCwPFM4KM7:TR?=	M2\zUnNCVkeHUh?=
A204	M{CyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvuR2Y6UUN3ME2wMlAyOjF6IN88US=>	NGXQOI5USU6JRWK=
GDM-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwMEG4N\|Mh\|ryP	NGLYOo5USU6JRWK=
AN3-CA	NIDOTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXnVlBOUUN3ME2wMlAyQDd\|IN88US=>	MXrTRW5ITVJ?
BL-70	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4q0PWlEPTB;MD6wNlE6QSEQvF2=	MX3TRW5ITVJ?
Daudi	MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXvdo9KSzVyPUCuNFI2OzdizszN	Mn\mV2FPT0WU
KU812	M13mfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7ZTWM2OD1yLkCyPFQ5KM7:TR?=	NHTi[4hUSU6JRWK=
KG-1	NI\zTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrhOlFKSzVyPUCuNFMzQTRizszN	M3jqbHNCVkeHUh?=
DOHH-2	M4ruVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonwTWM2OD1yLkC0PFA{KM7:TR?=	NX75PGcxW0GQR1XS
HuO9	NHHsRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\BRVU3UUN3ME2wMlA2PDR6IN88US=>	MVfTRW5ITVJ?
EB2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHFVIdmUUN3ME2wMlA2PTd4IN88US=>	MnP0V2FPT0WU
G-402	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjEdmxKSzVyPUCuNFY{PDFizszN	MYXTRW5ITVJ?
SU-DHL-1	NXH6[5lET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3yNpM1UUN3ME2wMlA3Ozd7IN88US=>	NF;XSGNUSU6JRWK=
NCI-H719	NGL0e5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV[2U482UUN3ME2wMlA4QDh6IN88US=>	NHnsbFVUSU6JRWK=
MLMA	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLjTWM2OD1yLkC5NFYh\|ryP	MY\TRW5ITVJ?
KM12	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwMEm3N\|ch\|ryP	NY\kbI1sW0GQR1XS
SUP-T1	MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLNd2pKSzVyPUCuNFk6QDJizszN	Ml25V2FPT0WU
MZ1-PC	MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\iTWM2OD1yLkGxN\|M3KM7:TR?=	M4PxRXNCVkeHUh?=
MFE-296	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXpTWM2OD1yLkGxPFM6KM7:TR?=	MXrTRW5ITVJ?
ALL-PO	MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LVdWlEPTB;MD6xNlQ1OyEQvF2=	MoHRV2FPT0WU
GB-1	NGrwWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPLfJdKSzVyPUCuNVI2OTJizszN	M1nEd3NCVkeHUh?=
SIG-M5	M4\5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMUOzO{DPxE1?	NEi2dppUSU6JRWK=
P30-OHK	NX\KNFhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{m0NWlEPTB;MD6xOVY4OiEQvF2=	NXXOSnVYW0GQR1XS
NCI-H716	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPKSZdKSzVyPUCuNVYzPjZizszN	MXfTRW5ITVJ?
MPP-89	MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMU[5N\|Mh\|ryP	MlWwV2FPT0WU
SF126	MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;KVGlEPTB;MD6xO\|A3OyEQvF2=	MkT0V2FPT0WU
CTB-1	NHHrNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXCSYZKSzVyPUCuNVc{OTZizszN	M4jlSnNCVkeHUh?=
CA46	NIrmcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUOyXJZxUUN3ME2wMlE4PDh7IN88US=>	M3fCbnNCVkeHUh?=
NCI-H520	M1TOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjGNZhKSzVyPUCuNVc4OzJizszN	M2DPSXNCVkeHUh?=
CAL-85-1	NYPvc2VjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LiNWlEPTB;MD6xO\|kzPyEQvF2=	NYXpSItsW0GQR1XS
NCI-H2342	NXv2eXZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXiTHhNUUN3ME2wMlE5PTd5IN88US=>	M3XPOHNCVkeHUh?=
697	Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\0b\|NNUUN3ME2wMlE5QDdzIN88US=>	MkLCV2FPT0WU
NY	MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\JcWM6UUN3ME2wMlE6Ojh5IN88US=>	MUjTRW5ITVJ?
T98G	NVnMO\|g2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjlXYtnUUN3ME2wMlE6OzF6IN88US=>	NFztTpBUSU6JRWK=
NCI-H1703	M2\UVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDYTWM2OD1yLkG5OlE2KM7:TR?=	MoT6V2FPT0WU
NCI-H2087	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfyN2JKSzVyPUCuNlA1OzlizszN	MWPTRW5ITVJ?
PF-382	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMkC4O\|Mh\|ryP	MnHRV2FPT0WU
HCT-116	MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMkGwOlkh\|ryP	NV;QO4MzW0GQR1XS
CAKI-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnO1TWM2OD1yLkKxOlY3KM7:TR?=	NGnMb25USU6JRWK=
CCF-STTG1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;YTWM2OD1yLkKyOFc2KM7:TR?=	NFjidXZUSU6JRWK=
D-392MG	M3nvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLvfVVKSzVyPUCuNlMyPzdizszN	MWTTRW5ITVJ?
RT-112	M16wUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwMkO3PVUh\|ryP	NHTYZ3BUSU6JRWK=
MES-SA	M33JXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\tTGlEPTB;MD6yOFE5PyEQvF2=	MXjTRW5ITVJ?
LC-2-ad	NE\Qb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLISo1nUUN3ME2wMlI1OjZ3IN88US=>	NYnqO4tnW0GQR1XS
NOS-1	NV7tc3d2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIj0fHBKSzVyPUCuNlQ{PjdizszN	MYnTRW5ITVJ?
NALM-6	M2\xNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PnNWlEPTB;MD6yOVU1OyEQvF2=	Mn\kV2FPT0WU
TE-15	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF30SWhKSzVyPUCuNlYxQTFizszN	MlXZV2FPT0WU
786-0	NX\YVnJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH71WWVKSzVyPUCuNlYzOjhizszN	NIrZcG9USU6JRWK=
IST-MES1	NGG4dZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrXT445UUN3ME2wMlI3QDJ7IN88US=>	Mn7PV2FPT0WU
KYSE-180	NUP1UnZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMk[4PVEh\|ryP	MkTiV2FPT0WU
YT	Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\3R2lEPTB;MD6yOlk4PCEQvF2=	NVLEcZVrW0GQR1XS
A427	NY[0Tmx6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;oTWM2OD1yLkK3NlY1KM7:TR?=	MUjTRW5ITVJ?
KYSE-450	NUT5TXM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPEdnNKSzVyPUCuNlc{OjlizszN	M2D6OXNCVkeHUh?=
HuH-7	MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMke3OlMh\|ryP	MVTTRW5ITVJ?
CAS-1	M1nVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjPW2ZrUUN3ME2wMlI5OzB\|IN88US=>	M{PKN3NCVkeHUh?=
KURAMOCHI	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTBwMki0NVkh\|ryP	NIW3eWtUSU6JRWK=
ACHN	NVTW[ZJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMkmzNlMh\|ryP	MWXTRW5ITVJ?
HGC-27	MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwMkmzOVMh\|ryP	NWTGbnlXW0GQR1XS
A172	M{Dabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwMkm1O\|ch\|ryP	NWnLWJJbW0GQR1XS
SNU-449	NX\ROJV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TVZ2lEPTB;MD6yPVk3PCEQvF2=	NYO3N\|lDW0GQR1XS
SW982	NFK1folIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwMkm5O\|gh\|ryP	MWXTRW5ITVJ?
EFO-21	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrr[o5KSzVyPUCuN\|A1OTFizszN	NWD6Zmo3W0GQR1XS
NCI-H2030	M2\uXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfKTWM2OD1yLkOxNVY1KM7:TR?=	M3\XSnNCVkeHUh?=
HT-144	NFLyXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvQOJlwUUN3ME2wMlMyOjhizszN	M{W2fXNCVkeHUh?=
MFE-280	NWm3[pBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwM{G0OVMh\|ryP	NHfqOGRUSU6JRWK=
SK-LU-1	MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnr4TWM2OD1yLkOxOFY3KM7:TR?=	MV7TRW5ITVJ?
NCI-H2052	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rDOmlEPTB;MD6zNVQ5PCEQvF2=	NFfuc\|BUSU6JRWK=
SK-HEP-1	NX\Ub4xET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGL0b2pKSzVyPUCuN\|M{PjhizszN	NVPGWnh{W0GQR1XS
QIMR-WIL	NUXGbYNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGro[VNKSzVyPUCuN\|M1OjRizszN	NGDHc\|RUSU6JRWK=
A2780	M4q1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDlOWxHUUN3ME2wMlM1OzB2IN88US=>	NFvvUZVUSU6JRWK=
ACN	NHzISndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInGWldKSzVyPUCuN\|Q5PzNizszN	M1qzNXNCVkeHUh?=
BxPC-3	NIDScVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwM{S5PFkh\|ryP	M4D2WnNCVkeHUh?=
BCPAP	NGW2e2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwM{[wNFEh\|ryP	MYfTRW5ITVJ?
HOP-62	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Xwd2lEPTB;MD6zOlExPiEQvF2=	MnTvV2FPT0WU
SW1710	NFzYUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHhdlhpUUN3ME2wMlM3PDV3IN88US=>	NEK5fo5USU6JRWK=
OPM-2	NFnIbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rQfWlEPTB;MD6zOlQ4OyEQvF2=	NVm3fnl2W0GQR1XS
DBTRG-05MG	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHaVZNiUUN3ME2wMlM5ODV2IN88US=>	M3\HNnNCVkeHUh?=
SK-MEL-24	Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHY[29KSzVyPUCuN\|k4QTFizszN	MlXZV2FPT0WU
8305C	M3Premdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2robGlEPTB;MD6zPVc6OyEQvF2=	MV7TRW5ITVJ?
OVCAR-4	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LvfmlEPTB;MD60NVU5PiEQvF2=	MljPV2FPT0WU
HLE	NUDW[4J2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTBwNEG4OkDPxE1?	MojnV2FPT0WU
NCI-H747	NHrrXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXmzXYliUUN3ME2wMlQzOTN5IN88US=>	NFHnNZdUSU6JRWK=
SW780	NYKxU4d5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzRRldKSzVyPUCuOFI{PDZizszN	MmLFV2FPT0WU
KYSE-150	M2myZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXtd2JCUUN3ME2wMlQzPDF3IN88US=>	NWLD[IZGW0GQR1XS
H4	NWrle4tIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\ObGlEPTB;MD60NlQ2OSEQvF2=	MoDrV2FPT0WU
SW1088	NHm3OmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfyTWM2OD1yLkS0N\|kh\|ryP	NXzYUpR3W0GQR1XS
SF268	M3HnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mli1TWM2OD1yLkS0PFYh\|ryP	M17SWHNCVkeHUh?=
RT4	MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPNd2JFUUN3ME2wMlQ2OTFzIN88US=>	NYm3N4w5W0GQR1XS
NCI-H522	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2KyVmlEPTB;MD60OVI4KM7:TR?=	NYS0[GttW0GQR1XS
LCLC-97TM1	NHjiOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwNE[xPVUh\|ryP	MYXTRW5ITVJ?
CAL-39	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwNE[1NVkh\|ryP	NVvocm06W0GQR1XS
CAL-120	Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\GcpRKSzVyPUCuOFc3PDNizszN	M{fpW3NCVkeHUh?=
ESS-1	Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HvbGlEPTB;MD60O\|gzOSEQvF2=	MoK3V2FPT0WU
KARPAS-45	M3;0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnWUJhKSzVyPUCuOFg6OzNizszN	NWXweYJ5W0GQR1XS
DU-4475	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XPO2lEPTB;MD60PVUyOSEQvF2=	M{fKU3NCVkeHUh?=
VMRC-RCZ	NWPOT\|lIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFGx[GlKSzVyPUCuOFk6ODRizszN	NH7zNIlUSU6JRWK=
HOS	NYLXdFBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1mwd2lEPTB;MD61NFM3PSEQvF2=	NXjzflNDW0GQR1XS
MOLT-16	NYPrTlRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwNUG4NFgh\|ryP	MYPTRW5ITVJ?
RPMI-6666	M{nZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7CTWM2OD1yLkWyNVM2KM7:TR?=	NHTQfolUSU6JRWK=
K052	M13ZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInzT4VKSzVyPUCuOVIyPCEQvF2=	NWHWdZF{W0GQR1XS
EHEB	NX\hTZRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTBwNUKxPFIh\|ryP	MoHMV2FPT0WU
MFH-ino	NV3HWGhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvNWYljUUN3ME2wMlUzOzVzIN88US=>	MWHTRW5ITVJ?
A4-Fuk	NIXNNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\PSnhRUUN3ME2wMlUzPTJ6IN88US=>	MX3TRW5ITVJ?
SW1417	NUPLN5hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjzW2FKSzVyPUCuOVI4QDFizszN	M3jPcXNCVkeHUh?=
DoTc2-4510	MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXpUXFKSzVyPUCuOVQ6PThizszN	NXrpeWpDW0GQR1XS
TE-12	MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPSTlA2UUN3ME2wMlU2PzN3IN88US=>	M3nUWnNCVkeHUh?=
8-MG-BA	NFTjTWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPuNXFKSzVyPUCuOVYxPTZizszN	MnTJV2FPT0WU
ECC12	NX7qOGVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\xWGlEPTB;MD61OlU2QCEQvF2=	MkSzV2FPT0WU
CHL-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwNUe0OlMh\|ryP	M4XseXNCVkeHUh?=
LCLC-103H	NFTQ[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3CfGNGUUN3ME2wMlU5OzR2IN88US=>	NIX6ZmpUSU6JRWK=
OS-RC-2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDYbWNKSzVyPUCuOVg{PzlizszN	NWHz[mtOW0GQR1XS
RO82-W-1	M4fpXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwNUm2NVUh\|ryP	NWf5Z\|l7W0GQR1XS
A3-KAW	NGjKT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nM[WlEPTB;MD62NVQ3PyEQvF2=	M4HOTXNCVkeHUh?=
NCCIT	NH74c2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;oeGlEPTB;MD62NVcyPSEQvF2=	Ml;3V2FPT0WU
IST-SL2	Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XxbGlEPTB;MD62NlUzOiEQvF2=	MUDTRW5ITVJ?
GI-ME-N	MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwNkOwOlkh\|ryP	M4\EOXNCVkeHUh?=
ES6	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\jR\|ZKSzVyPUCuOlMzQTVizszN	M3\LTnNCVkeHUh?=
BL-41	NHTveZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoD3TWM2OD1yLk[zN\|UzKM7:TR?=	MW\TRW5ITVJ?
Ca-Ski	NFT6dHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLOTWM2OD1yLk[0PFEh\|ryP	MYXTRW5ITVJ?
HOP-92	NVvFNmlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NESwWFJKSzVyPUCuOlU3PzJizszN	MV7TRW5ITVJ?
SK-LMS-1	MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnH[phKSzVyPUCuOlY1PyEQvF2=	NEC3PWJUSU6JRWK=
EW-13	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjBdVY3UUN3ME2wMlY3Pzd7IN88US=>	NFfQb4tUSU6JRWK=
647-V	MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPURmlKSzVyPUCuOlgyPDhizszN	M3GzNHNCVkeHUh?=
JiyoyeP-2003	MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\RSHNKSzVyPUCuOlk4OzhizszN	Mmf2V2FPT0WU
WSU-NHL	MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7Ed45TUUN3ME2wMlcxQDh5IN88US=>	MWLTRW5ITVJ?
U-698-M	NXXpV242T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX23R5lVUUN3ME2wMlcyODZ\|IN88US=>	NXv3NYREW0GQR1XS
HC-1	M{DGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zQd2lEPTB;MD63NlQxPSEQvF2=	NYe5XYpOW0GQR1XS
8505C	MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrQbFdKSzVyPUCuO\|I4PDFizszN	M2\afXNCVkeHUh?=
HUTU-80	NUfCSHNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGWybGhKSzVyPUCuO\|M{PDlizszN	M{exNnNCVkeHUh?=
LB1047-RCC	NWP5TpJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwN{O1N\|gh\|ryP	MYfTRW5ITVJ?
GAMG	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwN{O2OVMh\|ryP	MWDTRW5ITVJ?
CAL-12T	NGPUW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk[0TWM2OD1yLkezPFc4KM7:TR?=	M3;IdnNCVkeHUh?=
NCI-SNU-1	M3LCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzXV4ZKSzVyPUCuO\|czPzhizszN	MY\TRW5ITVJ?
HTC-C3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwN{e0OVEh\|ryP	MWTTRW5ITVJ?
HPAF-II	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DyUGlEPTB;MD63O\|UxOSEQvF2=	NG\yd3hUSU6JRWK=
KGN	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3f2cmlEPTB;MD63PFA5OSEQvF2=	MmnBV2FPT0WU
EFO-27	NW\XO4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TkWmlEPTB;MD63PFc{OyEQvF2=	NGLmT\|lUSU6JRWK=
MEL-HO	M134PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLOUGpKSzVyPUCuO\|k1PDlizszN	NGf4RYFUSU6JRWK=
KYSE-270	M{fwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwOEC1Nlkh\|ryP	NFXP[45USU6JRWK=
NCI-H1755	NHnnTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwOEC3NVQh\|ryP	MmP0V2FPT0WU
MFM-223	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUizO3g4UUN3ME2wMlgyPDB5IN88US=>	M2fycHNCVkeHUh?=
G-361	NVHYV\|BiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwOEG4PVch\|ryP	MnyyV2FPT0WU
ETK-1	NV\B[YJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwOEK0OFEh\|ryP	NXXqZnJkW0GQR1XS
LU-99A	NW\vPFd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;PRVZKSzVyPUCuPFQ4ODFizszN	Ml;5V2FPT0WU
IST-MEL1	NVzBSJlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHJeFlLUUN3ME2wMlg2PzN{IN88US=>	NUjOPI9EW0GQR1XS
L-540	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwOEW4NFEh\|ryP	Ml7FV2FPT0WU
U-2-OS	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnoTWM2OD1yLki1PFQ3KM7:TR?=	NGnzbpFUSU6JRWK=
HT-1376	NIX2bGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwOE[wOVEh\|ryP	MoKzV2FPT0WU
COLO-680N	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwOEe5N\|Mh\|ryP	NHHQR\|VUSU6JRWK=
NCI-H1581	M{nNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwOEmyPVch\|ryP	MkK0V2FPT0WU
HuCCT1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPFPGFWUUN3ME2wMlg6PTR6IN88US=>	MkjPV2FPT0WU
BB30-HNC	M3;ndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3v1[mlEPTB;MD65NlQ3QSEQvF2=	NE\CSYpUSU6JRWK=
NCI-H2347	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYize5djUUN3ME2wMlk{Ojl{IN88US=>	NWPrUll3W0GQR1XS
G-401	MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3qxfGlEPTB;MD65N\|Y6PSEQvF2=	NU\OPZUzW0GQR1XS
NCI-H358	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrITWM2OD1yLkm1NFE1KM7:TR?=	MlvwV2FPT0WU
HCC1395	NEe1SZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHy0bFVKSzVyPUCuPVU1PjFizszN	M1;CTHNCVkeHUh?=
J82	NFrNZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwOUW1OFMh\|ryP	MUXTRW5ITVJ?
KE-37	NWnuUno{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnLTWM2OD1yLkm2N\|g4KM7:TR?=	NIra[W1USU6JRWK=
NOMO-1	M3SwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmX5TWM2OD1yLkm2OVY1KM7:TR?=	NV\PVm54W0GQR1XS
ML-2	M1nKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTBwOUm3OUDPxE1?	MWDTRW5ITVJ?
SW872	NHO0WZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{G2fGlEPTB;MD65PVc4PSEQvF2=	NXT2UohxW0GQR1XS
KYSE-520	NF\xbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;UPGlEPTB;MT6wNFQ6PCEQvF2=	MYnTRW5ITVJ?
HL-60	NH7Xe2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTFwMEC5O{DPxE1?	NH;acldUSU6JRWK=
HDLM-2	NVHEXFlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTFwMEGyOVIh\|ryP	M2TSVHNCVkeHUh?=
MIA-PaCa-2	M1Xrdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnOcHZKSzVyPUGuNFE{PzVizszN	M2DyV3NCVkeHUh?=
TCCSUP	M2jWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYe2T5YxUUN3ME2xMlAyPzN{IN88US=>	NYDkNXZmW0GQR1XS
SH-4	NVj0OG9[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTFwMEKyOFQh\|ryP	NEn6XmZUSU6JRWK=
MG-63	Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVf4cZVrUUN3ME2xMlAzPjF4IN88US=>	MoDoV2FPT0WU
NB6	NV3sfVA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3sWmpKSzVyPUGuNFMyODlizszN	MorFV2FPT0WU
CAL-54	NYnObIY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3mcJRuUUN3ME2xMlA{QTV7IN88US=>	MV;TRW5ITVJ?
DU-145	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjDdIZLUUN3ME2xMlA5ODd\|IN88US=>	NUfGeY96W0GQR1XS
HCE-4	NXHsPYlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NID6dJFKSzVyPUGuNFkzQDZizszN	MoT2V2FPT0WU
U-266	NFfwTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDsTWM2OD1zLkC5OlM{KM7:TR?=	MUHTRW5ITVJ?
HT-1197	MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2n0S2lEPTB;MT6xNVQ{QCEQvF2=	M1zDXHNCVkeHUh?=
EW-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfoTWM2OD1zLkG0NVI5KM7:TR?=	Mn24V2FPT0WU
MHH-NB-11	NEXudopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTFwMUWzOlgh\|ryP	NHf6UG9USU6JRWK=
NCI-H2405	NFHZRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIL0Ro5KSzVyPUGuNVYyPiEQvF2=	MYDTRW5ITVJ?
COLO-668	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTFwMU[0PUDPxE1?	Mlz3V2FPT0WU
IMR-5	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTFwMU[5N\|Yh\|ryP	MX;TRW5ITVJ?
ARH-77	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3j6ZWlEPTB;MT6yNlkzPCEQvF2=	NF31bXhUSU6JRWK=
BHT-101	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHBVoZxUUN3ME2xMlI{PDlizszN	MWXTRW5ITVJ?
SCC-25	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXsTWM2OD1zLkKzOVM3KM7:TR?=	M4qwXHNCVkeHUh?=
NTERA-S-cl-D1	NFvZPHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlThTWM2OD1zLkK0N\|Q3KM7:TR?=	NHOwR2lUSU6JRWK=
MKN28	MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTFwMkW2N\|Yh\|ryP	MYXTRW5ITVJ?
KS-1	NXXBOmN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjqeZRKSzVyPUGuNlgzPjlizszN	MX\TRW5ITVJ?
NCI-H1734	NFHCZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXhW5htUUN3ME2xMlI5QTF\|IN88US=>	NF;0fYxUSU6JRWK=
ES7	NFmzeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTFwMkm1OFIh\|ryP	NWL0b\|FuW0GQR1XS
NCI-H838	NXzFT5JTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHvTWM2OD1zLkOwOlE2KM7:TR?=	MnrlV2FPT0WU
HEC-1	M2\Sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PqfWlEPTB;MT6zN\|c2PSEQvF2=	MoT2V2FPT0WU
ME-180	NUnjc\|B7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnldYN7UUN3ME2xMlM4QTl\|IN88US=>	NInoS5NUSU6JRWK=
MMAC-SF	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4m0b2lEPTB;MT6zPVU6PSEQvF2=	MmDOV2FPT0WU
IA-LM	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLXSoJ2UUN3ME2xMlQxQTF2IN88US=>	MXPTRW5ITVJ?
MN-60	M{HhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTFwNEOxNVQh\|ryP	NUDSUIFoW0GQR1XS
SIMA	M3\SZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUX1VotWUUN3ME2xMlQ5Pjh5IN88US=>	NX;SWlNJW0GQR1XS
NCI-H1770	M1TmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPzXVlvUUN3ME2xMlUzODV2IN88US=>	NYjqbFk5W0GQR1XS
ONS-76	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlOxTWM2OD1zLkWyN\|EyKM7:TR?=	NF2wNm1USU6JRWK=
LB771-HNC	M33GOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTFwNUO5NFYh\|ryP	MYrTRW5ITVJ?
SW48	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2[xc2lEPTB;MT61OFI1OyEQvF2=	M3i4R3NCVkeHUh?=
KYSE-140	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTFwNUW3OFEh\|ryP	Mn3oV2FPT0WU
SW626	Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTFwNUixOkDPxE1?	NILFPY1USU6JRWK=
MC-CAR	NWGwb5hXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTFwNUi2OlMh\|ryP	M4e2O3NCVkeHUh?=
D-336MG	M{Lob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTFwNkK5OEDPxE1?	M{nYOHNCVkeHUh?=
SK-MEL-3	NHO2SJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTmTWM2OD1zLk[zPVAzKM7:TR?=	NGW1bGlUSU6JRWK=
MHH-PREB-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13K[GlEPTB;MT62OFQ4OyEQvF2=	MVPTRW5ITVJ?
Calu-1	M{m0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHITWM2OD1zLk[1N\|g3KM7:TR?=	MXjTRW5ITVJ?
HCC1806	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPPTWM2OD1zLk[2OlEyKM7:TR?=	NWjpU2Y{W0GQR1XS
A101D	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTFwNk[3PFEh\|ryP	M1zU[nNCVkeHUh?=
A704	NYXCPHZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTFwNkizNVEh\|ryP	MmfYV2FPT0WU
LB831-BLC	MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnI[mtjUUN3ME2xMlY6QDV2IN88US=>	NF61ZZdUSU6JRWK=
RL95-2	NWfrVIlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXuTWM2OD1zLkexOFY{KM7:TR?=	MUnTRW5ITVJ?
RPMI-2650	M1m3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEW1OYlKSzVyPUGuO\|I4OTlizszN	MYfTRW5ITVJ?
NH-12	M3v5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzYcVJKSzVyPUGuO\|M1OjdizszN	MnXRV2FPT0WU
AGS	MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTFwN{[zOVgh\|ryP	NH[3dm5USU6JRWK=
NEC8	NFHLZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\TTWM2OD1zLke4PVk2KM7:TR?=	NXPITVVOW0GQR1XS
NCI-H2009	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{joV2lEPTB;MT63PVczOSEQvF2=	MWnTRW5ITVJ?
A498	M{Lwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fVO2lEPTB;MT64NVI5OiEQvF2=	NWrndFN5W0GQR1XS
NCI-H810	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XMPGlEPTB;MT64NVYxPiEQvF2=	M13oWXNCVkeHUh?=
SK-NEP-1	M3TkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnhN5I{UUN3ME2xMlg{PzZ5IN88US=>	MVLTRW5ITVJ?
D-542MG	MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrpdVRTUUN3ME2xMlg2QDVzIN88US=>	NFT0UI5USU6JRWK=
KNS-42	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vTfGlEPTB;MT64OlI3PiEQvF2=	NVrxfnl5W0GQR1XS
NCI-H2452	M3HxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGj2blBKSzVyPUGuPFkxPzRizszN	MWnTRW5ITVJ?
SK-MEL-2	NGnLTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLXTWM2OD1zLkmwNlcyKM7:TR?=	NWLOWlZCW0GQR1XS
OVCAR-5	M1T0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrhZ4ZVUUN3ME2xMlkxPjd3IN88US=>	NEe1XGVUSU6JRWK=
SNG-M	M4r6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGj5T3RKSzVyPUGuPVU5PThizszN	M1LWOHNCVkeHUh?=
A673	M{CzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;ifItKSzVyPUGuPVc2OTZizszN	NUPn[XlQW0GQR1XS
L-428	MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnv0TWM2OD1zLkm5NVc6KM7:TR?=	MnnZV2FPT0WU
KM-H2	NF\UWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTJwMEGwPUDPxE1?	NVfPSG1rW0GQR1XS
MC-IXC	NU\Bb5dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljDTWM2OD1{LkCyNlc{KM7:TR?=	M3nFTHNCVkeHUh?=
COLO-678	M1;wVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTJwMESyNFch\|ryP	NX3kTXk3W0GQR1XS
MEL-JUSO	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTJwMEe4OVEh\|ryP	M2XyN3NCVkeHUh?=
HCC38	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmj0TWM2OD1{LkC4OFM{KM7:TR?=	NH[wTotUSU6JRWK=
UACC-62	MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTJwMEi4OVUh\|ryP	MV3TRW5ITVJ?
OAW-42	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrmS45UUUN3ME2yMlA6PzFzIN88US=>	NYPOdIM5W0GQR1XS
LB996-RCC	M2fnUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfUTWM2OD1{LkGzPFE4KM7:TR?=	MVnTRW5ITVJ?
COR-L105	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjTeGpjUUN3ME2yMlE3Ozd\|IN88US=>	MV3TRW5ITVJ?
RCC10RGB	NILnW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{[wPGlEPTB;Mj6xPFU4PiEQvF2=	MVXTRW5ITVJ?
A431	NYmyS\|dIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITGeFVKSzVyPUKuNVkxOTlizszN	NIfkXGRUSU6JRWK=
NCI-H292	NUHmRnBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfxTWM2OD1{LkKzPVUyKM7:TR?=	MkToV2FPT0WU
SK-UT-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTJwM{OxPFQh\|ryP	M3exPXNCVkeHUh?=
PANC-08-13	NGfCXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fVOGlEPTB;Mj6zN\|I{PSEQvF2=	M2ruVXNCVkeHUh?=
ST486	NHfCXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rl[2lEPTB;Mj60NVA1QCEQvF2=	M1Wxd3NCVkeHUh?=
SJSA-1	MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTJwNEGyO\|Eh\|ryP	Mn7qV2FPT0WU
RKO	M1HyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkSwTWM2OD1{LkSyNFI6KM7:TR?=	MnfrV2FPT0WU
NCI-H1793	MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFX0Om5KSzVyPUKuOFQxOjlizszN	NG[1SYFUSU6JRWK=
639-V	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\UcGlEPTB;Mj60OVM5OiEQvF2=	NYrwRWtpW0GQR1XS
ES3	NVjVWJo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELBWWlKSzVyPUKuOFk4OzdizszN	NHHxVZhUSU6JRWK=
NCI-H1792	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlH0TWM2OD1{LkW2PFI3KM7:TR?=	MlHQV2FPT0WU
NCI-H1651	MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHLbYRKSzVyPUKuOVgzOSEQvF2=	Moi5V2FPT0WU
SN12C	NVPDfHdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHm[YFmUUN3ME2yMlU5PDh5IN88US=>	NWDhfpI5W0GQR1XS
COLO-679	NEjmZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NID4OmJKSzVyPUKuOVg3ODVizszN	NHLxNIVUSU6JRWK=
U-118-MG	NXO0TIc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInJe\|ZKSzVyPUKuOVg5PzJizszN	NYTLUZdJW0GQR1XS
Ramos-2G6-4C10	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTJwNkS4NFch\|ryP	MY\TRW5ITVJ?
HCT-15	NV\TbZJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jtRmlEPTB;Mj62PFc6OiEQvF2=	MmW4V2FPT0WU
MDA-MB-157	NU[5c2d4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWT6XXpuUUN3ME2yMlcxPzR5IN88US=>	M{n2UXNCVkeHUh?=
K5	NFXVNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfsRllpUUN3ME2yMlcyQDR3IN88US=>	NWTyOFNVW0GQR1XS
MKN45	NHLqOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIr2W3JKSzVyPUKuO\|M{PjZizszN	MWPTRW5ITVJ?
DMS-273	M3jORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWCxT2FmUUN3ME2yMlc2PjN{IN88US=>	MWfTRW5ITVJ?
C8166	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7MdXdKSzVyPUKuO\|g2OTNizszN	MlfTV2FPT0WU
Calu-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTJwN{i5Olkh\|ryP	M{\ocXNCVkeHUh?=
SNB75	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVH2WZNOUUN3ME2yMlg5PTN3IN88US=>	M3PiSHNCVkeHUh?=
BFTC-905	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHr3dY9KSzVyPUKuPVAyQTFizszN	Mkj5V2FPT0WU
C-4-II	NFrnbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrhTWM2OD1{LkmxN\|U{KM7:TR?=	MWLTRW5ITVJ?
MS-1	NIXhS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofGTWM2OD1{Lkm2O\|Y6KM7:TR?=	M1TkU3NCVkeHUh?=
A375	NU\FNItMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\TUYNTUUN3ME2zMlA5OTh2IN88US=>	M{LPW3NCVkeHUh?=
KYSE-70	NWHiT3VGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmOwTWM2OD1\|LkC4PFgzKM7:TR?=	MkPqV2FPT0WU
KYSE-510	MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\ucXBTUUN3ME2zMlExQTl3IN88US=>	NGraVIhUSU6JRWK=
LN-405	NGjje3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\ze2lEPTB;Mz6xN\|UyQCEQvF2=	NFPDPWRUSU6JRWK=
BOKU	MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rFbGlEPTB;Mz6xOFI2PiEQvF2=	MmnGV2FPT0WU
TE-10	NVTmPJVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XCUGlEPTB;Mz6xO\|M3OiEQvF2=	M{XPUHNCVkeHUh?=
MKN1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDLTJM6UUN3ME2zMlE5PDh\|IN88US=>	NF;CXJVUSU6JRWK=
M059J	MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\RTnBKSzVyPUOuNlAyPzNizszN	NInUOFZUSU6JRWK=
GOTO	M1rESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTNwMkKwN\|kh\|ryP	M2nXRXNCVkeHUh?=
DK-MG	MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPVWodkUUN3ME2zMlI2QTd4IN88US=>	M{fLcHNCVkeHUh?=
NCI-H727	NV3aZoo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{j6bWlEPTB;Mz6yOlU5KM7:TR?=	MoLzV2FPT0WU
NB12	MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVy3TJY5UUN3ME2zMlM{OjJ2IN88US=>	Mm[5V2FPT0WU
DOK	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTNwM{[xPFYh\|ryP	M4jHUHNCVkeHUh?=
KYSE-410	NHnwOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLpc2dFUUN3ME2zMlM3Ojh5IN88US=>	NF\F[WpUSU6JRWK=
AM-38	NH3FSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGK4dpdKSzVyPUOuN\|gxPTFizszN	MXTTRW5ITVJ?
GR-ST	M3f0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTNwNEW3N\|Ih\|ryP	NWqxPGtkW0GQR1XS
D-247MG	Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3f3emlEPTB;Mz60PFI3OyEQvF2=	Mn7sV2FPT0WU
TE-8	NF3sUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYGxSo9sUUN3ME2zMlQ6OzN\|IN88US=>	NXzFXVhDW0GQR1XS
LS-411N	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnUTYdXUUN3ME2zMlQ6Pjl{IN88US=>	M2rBfnNCVkeHUh?=
SK-MES-1	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTNwNU[0N\|Mh\|ryP	Mkj5V2FPT0WU
SF295	M4TLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWT4eZNSUUN3ME2zMlYyPTV{IN88US=>	MnHyV2FPT0WU
SK-MEL-30	NXHHbZdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIridVdKSzVyPUOuOlU6OjFizszN	NWPpc5p3W0GQR1XS
LB2241-RCC	NFztU5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7GSVFKSzVyPUOuOlYzPiEQvF2=	MUTTRW5ITVJ?
PC-14	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjpZXdsUUN3ME2zMlY3PDN5IN88US=>	NIj2SXRUSU6JRWK=
EW-7	MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTNwNke2PVMh\|ryP	NGfvfFlUSU6JRWK=
NMC-G1	M1TLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvRTWM2OD1\|LkexPFM4KM7:TR?=	MUnTRW5ITVJ?
TE-441-T	MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTNwN{OwNlgh\|ryP	MlHQV2FPT0WU
NCI-H1618	MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvEb3JKSzVyPUOuPFE5PzVizszN	M4nzdHNCVkeHUh?=
PANC-03-27	NWjOOlZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zZ[WlEPTB;Mz64NVkyPiEQvF2=	M1fkVHNCVkeHUh?=
NCI-H2228	MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jqfmlEPTB;Mz64N\|EzPiEQvF2=	MlzmV2FPT0WU
CAPAN-1	MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWmwcpBRUUN3ME2zMlg4ODB7IN88US=>	NULM[npDW0GQR1XS
KLE	NXzkTYRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfmUo9KSzVyPUOuPVA3PyEQvF2=	NUnE[YZIW0GQR1XS
Becker	NECyRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTNwOUK4OFkh\|ryP	MoLVV2FPT0WU
SK-PN-DW	NVTkS4drT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmC5TWM2OD12LkC3PVc1KM7:TR?=	MonkV2FPT0WU
Hs-578-T	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTRwMEizNFYh\|ryP	M2izeHNCVkeHUh?=
RS4-11	NHy4fVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3KzfmlEPTB;ND6xNVI2PSEQvF2=	M{T5SXNCVkeHUh?=
D-502MG	NXXWOpZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFu0e2lKSzVyPUSuNVY6QTdizszN	MYXTRW5ITVJ?
GI-1	M2H4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTRwMkiyPVkh\|ryP	NVPzSFFQW0GQR1XS
NCI-H209	NH;rdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUT5SmwyUUN3ME20MlM{PzhizszN	NYfjV3dFW0GQR1XS
SK-OV-3	MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInmXmxKSzVyPUSuOFgyPDlizszN	MUTTRW5ITVJ?
LOUCY	NFLxNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlyzTWM2OD12LkS4OFMzKM7:TR?=	MWXTRW5ITVJ?
NCI-H69	M363Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLYTWM2OD12LkWxO\|k{KM7:TR?=	NFrZTJJUSU6JRWK=
SCC-9	M3z4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzsWnVKSzVyPUSuOVMyPzJizszN	M4jKWnNCVkeHUh?=
NCI-H526	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTRwNUmyPVMh\|ryP	M{C5NnNCVkeHUh?=
NCI-H2170	M{XVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fodWlEPTB;ND62Olc4OSEQvF2=	NYnKbJE5W0GQR1XS
SR	NUDB[pJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTRwN{CwOFgh\|ryP	NX\pVZI1W0GQR1XS
CMK	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjyTWM2OD12LkeyNVAyKM7:TR?=	NXz5SFF5W0GQR1XS
COLO-829	MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTRwN{ewOFMh\|ryP	MnHWV2FPT0WU
HuO-3N1	MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7XbW9KSzVyPUSuPFMzQDFizszN	M1K1UXNCVkeHUh?=
5637	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTRwOUC0PFch\|ryP	MkLzV2FPT0WU
A253	Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTRwOUe3NFgh\|ryP	MXjTRW5ITVJ?
NB10	MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILjbW5KSzVyPUWuNFc1QTdizszN	MkHoV2FPT0WU
SF539	NHPpVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nPXWlEPTB;NT6wPVk2QSEQvF2=	NHfCSItUSU6JRWK=
HAL-01	M4H2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVe2PGJIUUN3ME21MlE1PjR3IN88US=>	NFPweFBUSU6JRWK=
MHH-ES-1	NYfrd5NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUS1cHpjUUN3ME21MlE3QTJ3IN88US=>	M{n1RXNCVkeHUh?=
DEL	M1i3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDDTWM2OD13LkK3OVgzKM7:TR?=	NELqfVlUSU6JRWK=
NCI-H1299	M17mNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTVwM{WwNFch\|ryP	MX3TRW5ITVJ?
ChaGo-K-1	NGj5VGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjKPZFuUUN3ME21MlM2OTB5IN88US=>	NFLodGtUSU6JRWK=
HMV-II	NUPxO3hHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHMe45KSzVyPUWuN\|k1OyEQvF2=	MUTTRW5ITVJ?
NB69	NGWyeZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{G4cWlEPTB;NT6zPVY{OSEQvF2=	NUTQcIx6W0GQR1XS
NCI-H1882	M3XzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLPUnM{UUN3ME21MlQ{OzZ2IN88US=>	M3rHdHNCVkeHUh?=
SNU-475	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjETWM2OD13LkS3NVcyKM7:TR?=	MkntV2FPT0WU
RXF393	NI[5VJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTVwNEi0PVQh\|ryP	MV;TRW5ITVJ?
CAL-51	NGjBWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzPUHNQUUN3ME21MlYzQDV\|IN88US=>	MYjTRW5ITVJ?
SW1573	NF;ENlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PXeWlEPTB;NT62N\|U{PCEQvF2=	NWfIXXJxW0GQR1XS
GCT	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvwWYhrUUN3ME21Mlc2QTJ7IN88US=>	NFm3eIpUSU6JRWK=
COR-L88	MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvPWJRmUUN3ME21Mlc3QDR4IN88US=>	M3XZV3NCVkeHUh?=
MDA-MB-134-VI	MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLkVJJEUUN3ME21Mlg4PTN4IN88US=>	MXfTRW5ITVJ?
NB5	NXf4RYtDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LSNWlEPTB;NT65NlQ1KM7:TR?=	MWrTRW5ITVJ?
GMS-10	NV:wWndiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVftVpRzUUN3ME21Mlk3QDZzIN88US=>	NW\EN2p2W0GQR1XS
CHP-212	NVvLS5pNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnTenY2UUN3ME22MlQ5OjZ5IN88US=>	MoTJV2FPT0WU
TE-11	NV;abnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfBTWM2OD14LkW1NVgzKM7:TR?=	NXyxXGJ1W0GQR1XS
SW962	M1LoTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTZwNkW3O\|Qh\|ryP	M2jKNXNCVkeHUh?=
MZ2-MEL	NULnRZI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLvTWM2OD14LkiyNFEyKM7:TR?=	NFWzT3RUSU6JRWK=
C-33-A	NHi5NIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTZwOUG2PFgh\|ryP	M2C1NHNCVkeHUh?=
IGR-1	MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYOwRpZ7UUN3ME22Mlk4QDJ4IN88US=>	NVLifVlyW0GQR1XS
MOLT-4	M1vadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLreGRSUUN3ME23MlE2PDB4IN88US=>	MVLTRW5ITVJ?
NCI-H1650	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTdwMkewOFYh\|ryP	M{nLc3NCVkeHUh?=
AsPC-1	NULIelduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\JTWM2OD15LkK4OlA2KM7:TR?=	M3;ydXNCVkeHUh?=
SNU-C2B	M2O0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTMTWM2OD15LkK5OVcyKM7:TR?=	MWLTRW5ITVJ?
MKN7	NIjlb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nvXGlEPTB;Nz6zO\|I{PSEQvF2=	NX[3TWVNW0GQR1XS
SW620	NV;PNnpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7sWXZKSzVyPUeuN\|gzODVizszN	NGrIO\|dUSU6JRWK=
SK-MEL-28	NWTxVI5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTdwNEC3PVgh\|ryP	NV\DfpJQW0GQR1XS
TE-6	M2f5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU[4NoxxUUN3ME23MlQ1QTB6IN88US=>	MVzTRW5ITVJ?
D-263MG	NYi2OWtZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXKzR3JyUUN3ME23MlQ2PzZ{IN88US=>	MoGyV2FPT0WU
NCI-H1355	NUXHOW5QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrtTWM2OD15Lke3NFI6KM7:TR?=	MXXTRW5ITVJ?
DSH1	M1roU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnu3TWM2OD15Lke5O\|YzKM7:TR?=	M3SxR3NCVkeHUh?=
NCI-H460	MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nGc2lEPTB;OD6wNFY6PCEQvF2=	M3PGd3NCVkeHUh?=
NCI-H1563	NF7oOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnjTWM2OD16LkC3OVA5KM7:TR?=	MX;TRW5ITVJ?
SW948	M{jmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfneGVwUUN3ME24MlExPzR2IN88US=>	NYSx[5FxW0GQR1XS
LK-2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRThwMUK4N\|Mh\|ryP	MkXFV2FPT0WU
HT-1080	M{\nPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\STWM2OD16LkGzNVc2KM7:TR?=	NXXhcWZWW0GQR1XS
NCI-H441	M2\FUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRThwMUmzJO69VQ>?	M3;ZO3NCVkeHUh?=
HSC-4	NYfYZZJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvXTWM2OD16LkK4O\|Ih\|ryP	NXrEdW03W0GQR1XS
LXF-289	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7CcFJiUUN3ME24MlM2QTR\|IN88US=>	NXn4SpBMW0GQR1XS
MRK-nu-1	M2DlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17jTmlEPTB;OD6zOlMxPCEQvF2=	NYrMR2gzW0GQR1XS
no-11	M2nhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3z6XGlEPTB;OD60O\|E{OyEQvF2=	NGXYfWtUSU6JRWK=
SNU-387	M2fVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\kSWtZUUN3ME24MlY{OjR4IN88US=>	NU\hN\|NHW0GQR1XS
Detroit562	NYqxXGNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3f4O2lEPTB;OD63OVQ2PSEQvF2=	MoDXV2FPT0WU
SW954	NYPScXc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXT6NXdjUUN3ME24Mlc3QDN{IN88US=>	MYDTRW5ITVJ?
P12-ICHIKAWA	Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHhTVVKSzVyPUiuO\|g6PCEQvF2=	NV;y[pZJW0GQR1XS
TE-9	MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRThwOEGwOlIh\|ryP	MkfzV2FPT0WU
NB13	MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvXTWM2OD16LkizO\|k3KM7:TR?=	M4CwUHNCVkeHUh?=
BPH-1	M1vCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLTTWM2OD16Lki1NFgyKM7:TR?=	Mlz0V2FPT0WU
KMOE-2	M3fhWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TvWGlEPTB;OD64O\|g6OiEQvF2=	MnvPV2FPT0WU
RPMI-8402	NGXEXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjHTWM2OD16Lki5PVI3KM7:TR?=	M1rGc3NCVkeHUh?=
OVCAR-3	NF\Bb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVftPY5uUUN3ME24Mlk4PzN{IN88US=>	NVi2ZpR7W0GQR1XS
NCI-H2196	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHOWVdKSzVyPUiuPVg3ODZizszN	MnHwV2FPT0WU
MZ7-mel	Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTBTJBjUUN3ME25MlA{PDZizszN	NHTUUlhUSU6JRWK=
GP5d	MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTyV4poUUN3ME25MlA3OzF\|IN88US=>	Mon5V2FPT0WU
NCI-N87	MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fyO2lEPTB;OT60OFc{OSEQvF2=	MUfTRW5ITVJ?
EW-16	M{i4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7NNZlKSzVyPUmuOFQ5PDhizszN	NX61bFNEW0GQR1XS
Calu-6	NH\t[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3qUplKSzVyPUmuOFk4ODNizszN	MVrTRW5ITVJ?
LC4-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTlwNkK1O{DPxE1?	NEG3XZVUSU6JRWK=
CCRF-CEM	M1r3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLWTWM2OD17Lk[4O\|Y3KM7:TR?=	NGPhPXVUSU6JRWK=
BC-1	NFrXTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUG1UVRqUUN3ME25Mlc5QTlizszN	MlXhV2FPT0WU
NCI-SNU-16	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nZZmlEPTB;OT63PVQ6PSEQvF2=	NFm2O5pUSU6JRWK=
NCI-H28	NF3xZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfZd49KSzVyPUmuPFQ6OzNizszN	NFjFcJdUSU6JRWK=
SBC-1	NWi0eHBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLGTWM2OD1zMD6wO\|Ih\|ryP	MVfTRW5ITVJ?
TUR	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTFyLkG2OVch\|ryP	NFXNW2NUSU6JRWK=
MDA-MB-231	NI\rd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjwcFc3UUN3ME2xNE4zOTF2IN88US=>	NXPCRVN[W0GQR1XS
C3A	MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPhNnFKSzVyPUGwMlMyPzlizszN	MXLTRW5ITVJ?
SW1990	NGrUTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1e2dWlEPTB;MUCuN\|I5KM7:TR?=	NEPqS2pUSU6JRWK=
NCI-H1993	M1TlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVi3coNCUUN3ME2xNE42Pjl\|IN88US=>	NYfrVot5W0GQR1XS
SK-CO-1	M3z1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1H2fWlEPTB;MUCuO\|c4KM7:TR?=	M3W5[3NCVkeHUh?=
OAW-28	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1K2PGlEPTB;MUCuPVg5QCEQvF2=	NIOwdYpUSU6JRWK=
HN	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTFzLkGxN\|Eh\|ryP	MniwV2FPT0WU
NCI-H1304	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHsTWM2OD1zMT6xOVc3KM7:TR?=	NGPwcIJUSU6JRWK=
Daoy	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PiXmlEPTB;MUGuOFM{PiEQvF2=	M1;WZXNCVkeHUh?=
VA-ES-BJ	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTFzLkexPVUh\|ryP	MUXTRW5ITVJ?
MCF7	NULlcZpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M336S2lEPTB;MUGuPFEzPiEQvF2=	Mm\IV2FPT0WU
VM-CUB-1	MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHYRmVYUUN3ME2xNU46ODlzIN88US=>	M{P5dnNCVkeHUh?=
IPC-298	NXzPfo5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTsXpd1UUN3ME2xNU46Ozh\|IN88US=>	Ml7OV2FPT0WU
NCI-H2126	NVfjSpdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoizTWM2OD1zMj6wNlE5KM7:TR?=	NEP5OWtUSU6JRWK=
OVCAR-8	M3X5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33vemlEPTB;MUKuNVE1OSEQvF2=	NICwSVFUSU6JRWK=
SJRH30	NH\WRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTJSZpKSzVyPUGyMlIzQTlizszN	M{HDVnNCVkeHUh?=
DMS-53	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvKTGlKSzVyPUGyMlI3PDlizszN	NVLHSIU5W0GQR1XS
NCI-H322M	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rSUWlEPTB;MUKuN\|M2PyEQvF2=	NXfib5dkW0GQR1XS
RVH-421	NXW5XlRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfUXnM{UUN3ME2xNk41QTB2IN88US=>	M2TxVHNCVkeHUh?=
Raji	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTF{Lk[xOEDPxE1?	Ml\rV2FPT0WU
MDA-MB-415	NYnaPFV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{[4XWlEPTB;MUKuOlQ1PCEQvF2=	M4jSc3NCVkeHUh?=
EFE-184	NYHMdVV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moq2TWM2OD1zMj63NVA3KM7:TR?=	NWPhOIExW0GQR1XS
BFTC-909	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zKbWlEPTB;MUKuPVI1PyEQvF2=	MmqxV2FPT0WU
BHY	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLaTWM2OD1zMz6zN\|kh\|ryP	NWLMWXhMW0GQR1XS
YKG-1	NVnpfmFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTx[WxKSzVyPUGzMlM4PDlizszN	Mn7RV2FPT0WU
EW-3	NWfyNnFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7KcYZKSzVyPUGzMlcyPjNizszN	NIHucI1USU6JRWK=
HCC1143	NYPSfohzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYj2S2JRUUN3ME2xN{44PDN5IN88US=>	NFuwbY9USU6JRWK=
REH	NXnVdldrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGS1c4VKSzVyPUGzMlg6QDJizszN	NVPxPFJ5W0GQR1XS
CESS	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknMTWM2OD1zMz65OFg6KM7:TR?=	MWrTRW5ITVJ?
EFM-19	MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHaTWM2OD1zND6xNVEzKM7:TR?=	NGXBfJVUSU6JRWK=
U031	M2XQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfEV5ZUUUN3ME2xOE41ODh3IN88US=>	NXzpeYZuW0GQR1XS
ES1	NXPz[pQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorFTWM2OD1zND60PFUyKM7:TR?=	MmPaV2FPT0WU
HSC-3	MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7iVmlKSzVyPUG0MlYzOTVizszN	MmT6V2FPT0WU
LOXIMVI	M4Tzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTF2LkewOlgh\|ryP	M2[4TnNCVkeHUh?=
A388	M4rqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfOSIZKSzVyPUG0Mlc2PTZizszN	NV7KUnNGW0GQR1XS
KP-N-YS	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnld\|g{UUN3ME2xOE44PzNizszN	Mn:5V2FPT0WU
Capan-2	NFu2U4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPWTWM2OD1zND63PFYh\|ryP	NWfTS4ZTW0GQR1XS
SKG-IIIa	NG\lN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;mNXdKSzVyPUG0Mlg5PjJizszN	MV\TRW5ITVJ?
HEL	NFrBd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfkTWM2OD1zND64PVk4KM7:TR?=	MlLYV2FPT0WU
BEN	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmftTWM2OD1zND65O\|Y3KM7:TR?=	M2DibHNCVkeHUh?=
MC116	NULzdFJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvScmpKSzVyPUG1MlE2QTlizszN	NU[0SINvW0GQR1XS
IGROV-1	NEKyc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvYNo5KSzVyPUG1MlI{OTdizszN	M{[4[3NCVkeHUh?=
NCI-H1648	M3LzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4e0WWlEPTB;MUWuOVMxPSEQvF2=	M4DqS3NCVkeHUh?=
ABC-1	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvZTWM2OD1zNT64NFM{KM7:TR?=	M3nsVHNCVkeHUh?=
EW-18	NX7oT4dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{[zZWlEPTB;MUWuPVk4QSEQvF2=	MkHGV2FPT0WU
BC-3	NFP0S3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTF4LkC1OlIh\|ryP	NXnYfJREW0GQR1XS
NCI-H1437	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTF4LkC2Olch\|ryP	Mlq1V2FPT0WU
SCC-15	M2HUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;JS4xKSzVyPUG2MlI5OjVizszN	MXnTRW5ITVJ?
TT	Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nGXWlEPTB;MU[uOVg5QCEQvF2=	M1vFbHNCVkeHUh?=
KINGS-1	NUjGWGFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13KWmlEPTB;MU[uPFI4OyEQvF2=	MV;TRW5ITVJ?
C32	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjVTWM2OD1zNj65O\|E4KM7:TR?=	MUXTRW5ITVJ?
SBC-5	M1X0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjLTWM2OD1zNz6xOFc6KM7:TR?=	MUHTRW5ITVJ?
NB1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH36ZYpKSzVyPUG3MlMyQDhizszN	MkHDV2FPT0WU
EB-3	M{[2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjKdVV2UUN3ME2xO{42PzZizszN	MkTUV2FPT0WU
NCI-H748	NETFd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIP5eGVKSzVyPUG3MlcxOzVizszN	NWXUPIc3W0GQR1XS
IST-SL1	MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NES4c3RKSzVyPUG3Mlc2OjZizszN	MV;TRW5ITVJ?
WM-115	NIrWeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XLXmlEPTB;MUeuPFA5PSEQvF2=	MoGwV2FPT0WU
NCI-H226	M2HWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1yxbmlEPTB;MUeuPVU1PiEQvF2=	NEjjRm1USU6JRWK=
CAL-33	NICxV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LySWlEPTB;MUiuNlc5OSEQvF2=	NXX1OFd2W0GQR1XS
SCC-4	MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrL[otCUUN3ME2xPE4{OjJ7IN88US=>	NF71S41USU6JRWK=
RMG-I	MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTF6Lk[5OFch\|ryP	NWf6V45uW0GQR1XS
KOSC-2	NHf1[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2H3SGlEPTB;MUiuO\|c1PiEQvF2=	MXTTRW5ITVJ?
A2058	NF\0NVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rBbmlEPTB;MUiuPFI2PSEQvF2=	NY\BfJhHW0GQR1XS
HCC70	M4DTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLGcGVKSzVyPUG5MlM5QTRizszN	MmrBV2FPT0WU
C2BBe1	NGLEPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXqcGJKSzVyPUG5MlQyPDhizszN	MYHTRW5ITVJ?
NCI-H650	NVnodpFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvCS4lJUUN3ME2xPU42QDl7IN88US=>	NF\M[W9USU6JRWK=
CAL-72	M13OVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTF7Lk[3N\|ch\|ryP	M3HXNHNCVkeHUh?=
L-363	NIXmWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrJRotKSzVyPUKwMlAzOTJizszN	MYTTRW5ITVJ?
SNU-423	MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHLNmIzUUN3ME2yNE4yODR\|IN88US=>	M1zKdXNCVkeHUh?=
PLC-PRF-5	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTJyLkO5NFYh\|ryP	MVvTRW5ITVJ?
SW1463	MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn:0TWM2OD1{MD60OVI2KM7:TR?=	NVzHeoNwW0GQR1XS
769-P	MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTJyLk[3Olkh\|ryP	NFHuU\|ZUSU6JRWK=
DMS-79	M2DOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXMRWtEUUN3ME2yNE45PDlizszN	M33PbnNCVkeHUh?=
Saos-2	NF\CTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTJyLkm1OVYh\|ryP	M4L3SXNCVkeHUh?=
CHP-126	M4D0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NECycGRKSzVyPUKxMlQ1PjJizszN	NHS0WWJUSU6JRWK=
SW837	Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHroZmNKSzVyPUKxMlQ6OzlizszN	M3XwdHNCVkeHUh?=
SHP-77	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzyNIZKSzVyPUKxMlYyOjJizszN	M1HnTXNCVkeHUh?=
DB	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1qzO2lEPTB;MkGuOlE1OiEQvF2=	M3S1U3NCVkeHUh?=
ES5	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PS[WlEPTB;MkGuOlg3PCEQvF2=	NF\0SJlUSU6JRWK=
COR-L23	M3PrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknTTWM2OD1{MT64NFUyKM7:TR?=	M4Tp[nNCVkeHUh?=
KU-19-19	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4G3[2lEPTB;MkGuPFk5OiEQvF2=	NXPqWJJYW0GQR1XS
T84	NIXpcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTJzLkm4NVkh\|ryP	M{LlVnNCVkeHUh?=
NCI-H630	NX\VcGtqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXaT3ZKSzVyPUKyMlU{PjNizszN	MVvTRW5ITVJ?
LU-165	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTJ{LkW1OEDPxE1?	M3n5VHNCVkeHUh?=
COLO-792	NIXL[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\RTWM2OD1{Mj63NVEyKM7:TR?=	NGrZcFNUSU6JRWK=
CAL-62	NV3weYNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzlXopKSzVyPUKyMlc2OTdizszN	NGHXOmFUSU6JRWK=
HCE-T	NYiwUFRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTJ{Lki2NFYh\|ryP	M2fPNHNCVkeHUh?=
BB65-RCC	M3T6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXkWZlrUUN3ME2yN{4xOzR2IN88US=>	NXPWOo9JW0GQR1XS
SiHa	M3HIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vqS2lEPTB;MkOuN\|k3QCEQvF2=	NWDmRoxHW0GQR1XS
NCI-H2081	NUXPSVZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlToTWM2OD1{ND6wOlQyKM7:TR?=	NWL5W5ZRW0GQR1XS
U251	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnzR3FSUUN3ME2yOE4xPjZ6IN88US=>	MUPTRW5ITVJ?
LoVo	M3;TXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHMOmVKSzVyPUK0MlkzQDJizszN	NUjWUWpbW0GQR1XS
GCIY	Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPmeZNFUUN3ME2yOU4zQDd5IN88US=>	M3PaTnNCVkeHUh?=
NUGC-3	Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\USXBKSzVyPUK1MlM{OTZizszN	NVrMdYF6W0GQR1XS
LNCaP-Clone-FGC	M1rLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\CTWM2OD1{NT6zOFk5KM7:TR?=	NYPnRXpZW0GQR1XS
PA-1	Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LkbmlEPTB;MkWuOlg{OyEQvF2=	MlO4V2FPT0WU
OE33	NVP1[WtRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfYTWM2OD1{NT62PFU{KM7:TR?=	MXLTRW5ITVJ?
HT-29	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\ldGlEPTB;MkWuO\|g4QSEQvF2=	M1TvdHNCVkeHUh?=
RCM-1	NV;WUGhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlu0TWM2OD1{NT65OlU3KM7:TR?=	MXTTRW5ITVJ?
NCI-H1522	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PwNmlEPTB;MkWuPVkyOSEQvF2=	MknvV2FPT0WU
LB373-MEL-D	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fq[mlEPTB;Mk[uNVcxQCEQvF2=	MV;TRW5ITVJ?
NCI-H1436	M1XQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlq0TWM2OD1{Nj6yO\|M5KM7:TR?=	MWXTRW5ITVJ?
COLO-824	M3TkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HaSmlEPTB;Mk[uOFAxOiEQvF2=	NFfmWJRUSU6JRWK=
CP50-MEL-B	M2ruWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTJ4LkW2O\|Uh\|ryP	M4XY[HNCVkeHUh?=
EGI-1	NWj4[\|ViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nVcmlEPTB;MkeuNlY6QCEQvF2=	NV7rbFJCW0GQR1XS
LAN-6	M2L3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGe0dWxKSzVyPUK3MlM2QThizszN	NYLVVZNjW0GQR1XS
GAK	NGXIPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHHZld4UUN3ME2yO{41OjJ3IN88US=>	NYr1[2RvW0GQR1XS
MDA-MB-175-VII	NV73TYE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jvV2lEPTB;MkeuOVA2OyEQvF2=	M3XyUnNCVkeHUh?=
JVM-2	NH;qd\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;2WWxoUUN3ME2yO{43PjJ{IN88US=>	MmqwV2FPT0WU
UACC-257	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFziUplKSzVyPUK3MlY5PzhizszN	MoTPV2FPT0WU
SW1783	NX3LPYNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\ZTWM2OD1{Nz63O\|g{KM7:TR?=	MVXTRW5ITVJ?
HT-3	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;rTWM2OD1{OD6yNVY3KM7:TR?=	NGK0VGtUSU6JRWK=
RL	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XQbWlEPTB;MkiuOVkyOSEQvF2=	NH6y[ppUSU6JRWK=
TK10	NWTMS\|VpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTJ6Lk[1N\|Uh\|ryP	NVqyR3FLW0GQR1XS
HT55	M3n2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrMdmNKSzVyPUK5MlA2PjVizszN	MYLTRW5ITVJ?
BT-20	M3vYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzVTWM2OD1{OT6wOVg3KM7:TR?=	M4S4bnNCVkeHUh?=
TGBC24TKB	MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7XZ3N{UUN3ME2yPU4yQDNzIN88US=>	M37n[nNCVkeHUh?=
HSC-2	M2jpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHH6R3FKSzVyPUK5MlMxODFizszN	NH\vXmNUSU6JRWK=
COLO-205	M17zSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHqTWM2OD1{OT6zPVQ1KM7:TR?=	MkHOV2FPT0WU
GT3TKB	NYP4T5FIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPLb2dKSzVyPUK5MlY5PzdizszN	NIXoemNUSU6JRWK=
T47D	M4XPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTJ7Lki1PFIh\|ryP	NFHFbYtUSU6JRWK=
OMC-1	M4nRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljETWM2OD1\|MD6xPVE6KM7:TR?=	MoTOV2FPT0WU
PFSK-1	M2XhRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTNzLkK2OVkh\|ryP	M2LPdXNCVkeHUh?=
JEG-3	Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTNzLkO1OlEh\|ryP	MVjTRW5ITVJ?
RD	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\HPG5WUUN3ME2zNU42OTF3IN88US=>	MYXTRW5ITVJ?
NCI-H64	M1TO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjpcHNKSzVyPUOyMlQyPzlizszN	M2\pZnNCVkeHUh?=
DMS-114	MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXGcW9UUUN3ME2zNk41OTh{IN88US=>	MnfuV2FPT0WU
NCI-H661	NHqzTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvoWJJ2UUN3ME2zNk43PTBzIN88US=>	M2PoU3NCVkeHUh?=
CAL-148	M3\lPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLROmhHUUN3ME2zNk43PjZ3IN88US=>	MlXKV2FPT0WU
HuP-T3	NYPsRmZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TBe2lEPTB;M{KuPVM{QCEQvF2=	NFToWnFUSU6JRWK=
ES4	NWSzbXVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVP4PYtJUUN3ME2zN{4yPzB3IN88US=>	M1vWUnNCVkeHUh?=
Ca9-22	MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXGfWFvUUN3ME2zN{41PjBzIN88US=>	NFzhbpRUSU6JRWK=
LP-1	NVPoN4hTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXOSFJKUUN3ME2zOE4xQSEQvF2=	MlfiV2FPT0WU
AU565	M3HheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XKcGlEPTB;M{SuOVA3QSEQvF2=	M3rXTHNCVkeHUh?=
MDA-MB-453	MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonQTWM2OD1\|NT6xOFI3KM7:TR?=	MoTJV2FPT0WU
SNU-C1	MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fkPWlEPTB;M{WuNVcyKM7:TR?=	MkDRV2FPT0WU
SW13	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NESxW41KSzVyPUO1MlQxPzZizszN	Moi3V2FPT0WU
NCI-H2122	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTN3LkW1PVgh\|ryP	NELFZ\|lUSU6JRWK=
NCI-H1395	M2nDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDUcohjUUN3ME2zOU43PjlzIN88US=>	M4PM[HNCVkeHUh?=
J-RT3-T3-5	NEPyOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTN4LkCyPVQh\|ryP	MmXvV2FPT0WU
COR-L279	NELuXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLNPWY2UUN3ME2zOk4yQThzIN88US=>	MYXTRW5ITVJ?
ATN-1	NYfZNox3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3q2[GlEPTB;M{[uPFUyPiEQvF2=	NHL1[JRUSU6JRWK=
HCC2998	Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M134TmlEPTB;M{[uPFU4OSEQvF2=	NVfHWpV7W0GQR1XS
UM-UC-3	NYK0OWRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHTTWM2OD1\|Nj64Olc2KM7:TR?=	MUHTRW5ITVJ?
DV-90	M2jiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDyTWM2OD1\|Nj65NFY4KM7:TR?=	MmfCV2FPT0WU
ES8	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTN4LkmzNVgh\|ryP	NXPkRZN5W0GQR1XS
YAPC	M3TNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmflTWM2OD1\|Nj65OlU1KM7:TR?=	MmjKV2FPT0WU
HCC1599	M33wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\4N3dKSzVyPUO3MlE3OThizszN	NE\WdJpUSU6JRWK=
UMC-11	NF\uN\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPWTWM2OD1\|Nz6yOVA{KM7:TR?=	MXXTRW5ITVJ?
THP-1	NIX1T\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rzWWlEPTB;M{euNlg3QCEQvF2=	MX;TRW5ITVJ?
OCUB-M	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnqd4xKSzVyPUO3MlI5QTFizszN	Ml;MV2FPT0WU
NCI-H1693	NYLiUIpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzaOmdKSzVyPUO3MlMzOzNizszN	MmPXV2FPT0WU
NCI-H345	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnUWVZNUUN3ME2zO{4{PjJ2IN88US=>	M3fPUHNCVkeHUh?=
COLO-800	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIX5RYZKSzVyPUO3MlU3PyEQvF2=	MVfTRW5ITVJ?
COLO-320-HSR	MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NISwRYZKSzVyPUO4MlM1QTJizszN	MX;TRW5ITVJ?
NCI-H596	Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnGc\|JKUUN3ME2zPE41PDh7IN88US=>	M3npUnNCVkeHUh?=
NCI-H187	M2XBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXXNlBCUUN3ME2zPE44OzR2IN88US=>	MVXTRW5ITVJ?
ECC4	MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37yWGlEPTB;M{muNFgyPCEQvF2=	NGTLXXNUSU6JRWK=
KP-4	NX7uOWJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjaTWM2OD1\|OT6xNlM2KM7:TR?=	Ml3hV2FPT0WU
NCI-H2227	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\Cc4VKSzVyPUO5MlM6PDlizszN	MWXTRW5ITVJ?
22RV1	NHfpb\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTN7LkizPVgh\|ryP	MW\TRW5ITVJ?
SAS	M{ntT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfmTWM2OD12MD6wPVYh\|ryP	M2W2VXNCVkeHUh?=
PANC-10-05	NH2wTppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjITWM2OD12MD6xPFI5KM7:TR?=	NWDIXppYW0GQR1XS
MDA-MB-468	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;zZnZKSzVyPUSwMlU{PDZizszN	MnPsV2FPT0WU
RPMI-7951	NGXvSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVu2VlRRUUN3ME20NU4zODd3IN88US=>	MV\TRW5ITVJ?
BB49-HNC	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTRzLkKxO\|kh\|ryP	NXT3SYJCW0GQR1XS
23132-87	M4jN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvZflJKSzVyPUSxMlI4OzJizszN	MlrWV2FPT0WU
HCC1569	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXVTWM2OD12MT6yPFg2KM7:TR?=	NUX6ZmtJW0GQR1XS
CP66-MEL	NWHyWXhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTRTWM2OD12Mj6xPFg3KM7:TR?=	MljmV2FPT0WU
K-562	M1nEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHG4OmFKSzVyPUSyMlI5PTRizszN	M2D1NnNCVkeHUh?=
OCI-AML2	NF\4S2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\vb2lEPTB;NEKuPFk4PCEQvF2=	NYC4bG85W0GQR1XS
SW756	NGjVSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfjb3FKSzVyPUSzMlA{QDhizszN	MnHlV2FPT0WU
M14	NEHCfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17ZWWlEPTB;NEOuN\|E5QSEQvF2=	MY\TRW5ITVJ?
NCI-H1623	M3;L[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfrTWM2OD12Mz60OlQh\|ryP	MmHEV2FPT0WU
KNS-81-FD	NETjcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFO4PGFKSzVyPUSzMlc3OiEQvF2=	MoXSV2FPT0WU
TGBC1TKB	NFPSZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTR\|LkmwPVkh\|ryP	MYnTRW5ITVJ?
RERF-LC-MS	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\tWGlEPTB;NEOuPVI5OSEQvF2=	NV7NR25MW0GQR1XS
PC-3	NUnUZYRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFH4bHFKSzVyPUS0MlQ{PDdizszN	MWTTRW5ITVJ?
HuP-T4	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHFZ4NpUUN3ME20OE41PDd2IN88US=>	NI\RU\|BUSU6JRWK=
NCI-H510A	NHnMUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTR2LkewPEDPxE1?	NGe0[JpUSU6JRWK=
LB2518-MEL	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTR2Lke5N\|ch\|ryP	NY\jZ3h7W0GQR1XS
TE-5	NETY[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHYSpdKSzVyPUS1Mlk2QDFizszN	MlXJV2FPT0WU
EW-24	NXfG[XZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTR4LkG3NlMh\|ryP	M{\ze3NCVkeHUh?=
LB647-SCLC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPYdYhpUUN3ME20Ok4zOTV3IN88US=>	MV;TRW5ITVJ?
NCI-H524	NVHOWVk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTR4LkexPFUh\|ryP	Mlj1V2FPT0WU
EW-11	MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLHTWM2OD12Nj65N\|c{KM7:TR?=	NGjqOGdUSU6JRWK=
KALS-1	MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrlUoMxUUN3ME20O{4zODZ4IN88US=>	MYfTRW5ITVJ?
BT-474	NIOy[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTR5LkSyNVYh\|ryP	NFviNplUSU6JRWK=
SK-N-AS	Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTR5Lki4PEDPxE1?	MoqzV2FPT0WU
HCC2157	NXvw[VR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1:0fWlEPTB;NEiuNFc3KM7:TR?=	M1f0THNCVkeHUh?=
HCC1954	NUfYeJdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTYTWM2OD12OD6xO\|A1KM7:TR?=	MkjEV2FPT0WU
FADU	MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTR6LkOwN\|Eh\|ryP	M1rGT3NCVkeHUh?=
S-117	NXjCd4RsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPCUo9mUUN3ME20PE4{QDF3IN88US=>	MX3TRW5ITVJ?
LS-1034	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTR6LkewOlch\|ryP	MUfTRW5ITVJ?
CAMA-1	M3f0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fteGlEPTB;NEmuOVU1OyEQvF2=	NVvRVJhJW0GQR1XS
LU-134-A	Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DsV2lEPTB;NEmuPFA5PSEQvF2=	NFfuWnNUSU6JRWK=
NCI-H1838	NHG3d5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2j2dWlEPTB;NEmuPFA5PyEQvF2=	NHezUlJUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

体内研究

Ponatinib抑制取自FLT3-ITD阳性AML病人的原代白血病细胞，而不抑制表达阴性FLT3的AML病人的白血病细胞。^[3]

激酶实验：^[1]	- 合并激酶实验: 通过同质时间分辨荧光共振能量转移法(TR-FRET)，使用纯化的人类野生型ABL激酶，T315I突变型ABL激酶，及生物素化的磷酸激酶底物肽: 生物素-EKKMAAEAIYAAPFAK-NH2，测定野生型ABL和T315I突变型ABL活性的抑制激酶反应在全LANCE激酶buffer (LKB)中进行，LKB包括20 mM NaHEPES（pH 为7.4）, 0.1 mg ⁄ mL BSA, 1 mM ATP, 10 mM MgCl₂, 及0.41 mM DTT，在提前用1% BSA（溶于PBS）包被的96孔板上4^oC下过夜。用于激酶反应，Ponatinib稀释物和野生型ABL, T315I突变型ABL (40 pM), 及底物肽(50 nM), 在室温下温育1小时（T315I突变型ABL）或2小时（野生型ABL）。加入15 nM 抑制剂, 6 nM 铕标记的磷酸酪氨酸抗体（磷酸化位点在第66为酪氨酸上），及60 nM 别藻蓝素标记的链酶亲和素，终止反应。实验板在室温下黑暗温育20分钟，使用Wallac Victor2V读数器读取615和665nm处的荧光值。在孔中数据平均值中插入抑制剂的3倍连续稀释液，再读取665nm处荧光值，计算IC50值。
细胞实验：^[1]	- 合并 Cell lines: Ba ⁄ F3细胞 Concentrations: 0-625 nM, 和0-10 µM Incubation Time: 72小时 Method: Ba/F3细胞系按每孔4×10³个细胞分布在96孔板上(4×10³)，和梯度浓度Ponatinib温育72小时。Ponatinib浓度范围为: 0-625 nM 作用于表达BCR-ABL细胞，0-10 µM 用于测定BCR-ABL阴性细胞。使用MTS实验测定细胞增殖，取三次平行实验平均值测定IC50值。 (Only for Reference)
动物实验：^[3]	- 合并 Animal Models: 皮下植入MV4-11细胞移植瘤(1×10⁷，50%基质胶中) 的雌性CB.17 SCID鼠 Dosages: 每天处理一次，持续4周 Administration: 口服饲喂处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 1% CMC Na	30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Ponatinib (AP24534) SDF

分子量	532.56
化学式	C₂₉H₂₇F₃N₆O
CAS号	943319-70-8
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04160546	Recruiting	Drug: Ponatinib 15 MG\|Drug: Acetylsalicylic acid 100 MG	Chronic Myeloid Leukemia Chronic Phase	Fundacion CRIS de Investigación para Vencer el Cáncer\|Incyte Biosciences UK\|Apices Soluciones S.L.	January 17 2020	Phase 2
NCT04070443	Recruiting	Drug: Ponatinib\|Drug: Imatinib	Philadelphia Chromosome Positive CML\|BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	November 13 2019	Phase 2
NCT03934372	Recruiting	Drug: Ponatinib	Acute Myeloid Leukemia\|Accelerated Phase Chronic Myeloid Leukemia\|Blast Phase Chronic Myeloid Leukemia\|Chronic Phase Chronic Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphocytic Leukemia\|Leukemia\|Lymphoma\|Solid Tumors	Incyte Biosciences International Sàrl\|Incyte Corporation	November 22 2019	Phase 1\|Phase 2
NCT03895671	Recruiting	Drug: Ponatinib\|Drug: Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	Versailles Hospital	June 19 2019	Phase 2
NCT03690115	Recruiting	Drug: Ponatinib 30 MG	Leukemia Myeloid Acute	Versailles Hospital	December 12 2018	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
回答：
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

选择性强的Bcr-Abl抑制剂

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
活性最高的Bcr-Abl抑制剂

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA批准的Bcr-Abl抑制剂

Dasatinib : Approved by FDA for CML and Ph+ ALL.
最新的Bcr-Abl抑制剂

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

研究领域

产品类型

定制您的化合物库

Ponatinib (AP24534)

客户使用Selleck生产的Ponatinib (AP24534)发表文献98篇：

产品安全说明书

Bcr-Abl抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Ponatinib (AP24534) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

技术支持

常见问题及建议解决方法

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

相关Bcr-Abl产品